Research
Research

Personalized Vaccine Aims to Stop Melanoma Recurrence After Surgery

By Marcus Reid ·

How the Personalized Vaccine Works

Researchers at Sutter Health are testing a personalized cancer vaccine designed to keep melanoma from coming back after tumor removal. The effort centers on a phase 2 clinical trial called KEYNOTE-942. Dr. Kevin Kim, chief of precision medicine, and Dr. Mohammed Kashani-Sabet, medical director of the Cancer Center, led the hospital's role in the study. The vaccine is tailored to each patient's specific tumor mutations.

The treatment works by training the immune system to recognize and attack cancer cells that may remain after surgery. This approach targets microscopic disease that standard therapies often miss. The study builds on earlier work showing that personalized vaccines can shrink tumors and extend survival in advanced melanoma.

The vaccine is made from a patient's own tumor tissue. Scientists identify the unique mutations driving that person's cancer. They then engineer a vaccine that presents these mutations to the immune system. The goal is to create long-lasting immunity against the specific cancer cells.

Could This Become Standard Care?

Dr. Kim explained that the vaccine acts like a custom-built weapon. It teaches the body to hunt down residual cancer cells. Dr. Kashani-Sabet noted that this method could reduce the need for aggressive chemotherapy. The trial is currently enrolling participants who have had melanoma removed surgically.

If the results hold, this vaccine could become a routine part of post-surgical care for melanoma patients. The trial will measure how often the cancer returns and how well patients tolerate the shots. Researchers hope to reduce recurrence rates significantly.

The approach mirrors strategies already used in other cancers. Personalized vaccines have shown promise in lung cancer and colorectal cancer trials. Melanoma is particularly responsive to immune therapy, making it a strong candidate for this technology.

Frequently Asked Questions

Is the vaccine safe for most patients? Early data suggests the vaccine is well tolerated. Most side effects are mild, including injection site reactions and low-grade fever. Serious adverse events are rare but monitored closely.

How long does it take to make the vaccine? The process typically takes several weeks. Tumor tissue is sent to a lab, mutations are identified, and the vaccine is produced. Patients receive the shots after surgery, before the cancer can establish itself again.

Will this replace other treatments? The vaccine is intended as an add-on therapy, not a replacement. It works alongside standard care to boost immune response. It is not a cure, but a tool to lower recurrence risk.